ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2417

Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America

Romina Nieto1, Lucia Hernandez2, Marina Scolnik3, Gisela Constanza Subils4, Veronica Saurit5, Verónica Gabriela Savio6, Valeria Arturi7, Boris Kisluk8, Luciana González Lucero9, Wilfredo Patiño Grageda10, María De Los Ángeles Gargiulo11, ODIRLEI MONTICIELO12, Angela Duarte13, Eduardo Borba14, Luciana Parente14, Edgard Reis Neto15, Oscar Neira16, Gustavo Aroca Martínez17, Antonio Iglesias Gamarra18, Paul Méndez-Patarroyo19, Rafael López20, Margarita Portela Hernandez21, Carlos Núñez-Álvarez22, Yelitza González Bello23, Jorge Isaac Velasco Santos24, Jorge Esquivel-Valerio25, Marcos Vázquez26, Maria Teresa Martinez de Filartiga27, Magaly Alva Linares28, Roberto Muñoz Louis29, Carina Pizzarossa30, Ana Carolina Ralle31, María Camila Riascos32, Joaquín Martínez Serventi33, Graciela Alarcon34, Bernardo Pons-Estel2 and Guillermo Pons-Estel35, and Grupo Latinoamericano de Estudio del Lupus (GLADEL), 1Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Hospital Italiano de Córdoba, Córdoba, Argentina, 5hospital privado universitario de cordoba, Córdoba, Argentina, 6Sección de Reumatología, Hospital Córdoba, Córdoba, Argentina, 7Hospital HIGA San Martín, La Plata, Argentina, 8Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, 9Hospital Padilla, Tucumán, Argentina, 10Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, 11Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, Buenos Aires, Argentina, 12HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, 13Universidad Federal de Pernambuco, Pernambuco, Brazil, 14Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 15Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil, 16Hospital del Salvador, Santiago de Chile, Chile, 17Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, 18Clínica de La Costa - Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, 19Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, 20Servicio de Reumatología. Hospital Luís Vernaza, Guayaquil, Ecuador, Guayaquil, Ecuador, 21Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, 22Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, 23Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, 24Hospital Central Dr. Ignacio Morones Prieto, Potosí, Mexico, 25Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 26Hospital de Clínicas I, Asunción, Paraguay, Asuncion del Paraguay, Paraguay, 27Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, 28Servicio de Reumatologia. Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, 29Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, 30Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, 31Hospital Señor del Milagro, Salta, Argentina, 32Centro de Referencia en Osteoporosis & Reumatología, Cali, Colombia, 33Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, CABA, Argentina, 34The University of Alabama at Birmingham, Oakland, CA, 35Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina

Meeting: ACR Convergence 2024

Keywords: Infection, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with complex multi-systemic involvement. Herpes zoster (HZ) is caused by the reactivation of latent varicella-zoster virus (VZV) in patients who had been exposed earlier. HZ infection is most commonly seen in elderly and immunocompromised individuals, including those with autoimmune diseases such as rheumatoid arthritis and SLE. In Latin America, information about the estimated frequency and impact of HZ in patients with SLE is scarce. The aim of this study was to assess the epidemiology and clinical characteristics of HZ and to identify factors associated with the first HZ episode in SLE patients.

Methods: GLADEL 2.0 is an observational multi-ethnic Latin-American SLE cohort. Forty-three centers from 10 Latin-American countries enrolled patients ≥18 years of age who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria. Baseline demographic, clinical, disease activity (SLEDAI), damage (SLICC/ACR Damage Index), laboratory and treatment data of patients with and without HZ events were examined. Continuous variables are presented as mean (±SD) or median (IQR) and categorical variables as count (percentage).  Prevalence was calculated as the proportion of patients with HZ infection out of the SLE patients in the GLADEL 2.0 cohort. Associated factors were identified and logistic regression analysis was performed to examine the adjusted effects of these characteristics on the probability of experiencing at least one episode of HZ infection. The results are presented as ORs and their 95% CIs. P values < 0.05 were considered statistically significant. All analyses were performed with R v4.2.2 (or a later version).

Results: Of the 1083 patients included in the GLADEL 2.0 cohort, 1073 were included in these analyses. A total of 83 HZ events were recorded at the baseline visit. The prevalence of HZ was 8.3% (CI: 6.8%-10.3%). SLE patients with history of HZ infection were more frequently female, with a higher frequency of cutaneous involvement (discoid lupus and alopecia), neurological involvement (psychosis and seizures), low complement, comorbidities and chronic renal failure (table 1). In terms of treatment, they also had a higher frequency of using methylprednisolone boluses, and immunosuppressants (IV cyclophosphamide, azathioprine, methotrexate, mycophenolate, rituximab and IV immunoglobulins). Multivariate analysis found that a history of psychosis and the use of methotrexate and mycophenolate were factors significantly associated with HZ events in these SLE patients (table 2).

Conclusion: In SLE patients from the GLADEL 2.0 cohort, the prevalence of HZ infection was found to be less than 10%. Neurological compromise and the use of immunosuppressants such as methotrexate and mycophenolate were associated with the occurrence of these events. It is important to be aware of the risk of HZ in SLE patients. Future research may be able to establish predictive factors of HZ occurrence in these patients.

Supporting image 1

Table 1. Sociodemographic, clinical and cumulative treatments according to Herpes Zoster events at cohort entry

Supporting image 2

Table 2. Univariable and multivariable logistic regression analyses of factors associated with the occurrence of herpes zoster infection


Disclosures: R. Nieto: None; L. Hernandez: None; M. Scolnik: AstraZeneca, 1, GlaxoSmithKlein(GSK), 1, 6, Janssen, 1, 6, Pfizer, 1, 6, Roche, 1, 6; G. Subils: None; V. Saurit: None; V. Savio: AbbVie/Abbott, 5, 6; V. Arturi: None; B. Kisluk: None; L. González Lucero: None; W. Grageda: None; M. De Los Ángeles Gargiulo: None; O. MONTICIELO: AbbVie/Abbott, 6, AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, UCB, 6; A. Duarte: None; E. Borba: None; L. Parente: AstraZeneca, 6, Janssen, 6; E. Reis Neto: AbbVie/Abbott, 12, Clinical research, AstraZeneca, 2, 5, 6, Bristol-Myers Squibb(BMS), 12, Clinical research, GlaxoSmithKlein(GSK), 2, 6, Novartis, 1, 6; O. Neira: None; G. Aroca Martínez: None; A. Iglesias Gamarra: None; P. Méndez-Patarroyo: None; R. López: None; M. Hernandez: None; C. Núñez-Álvarez: None; Y. González Bello: None; J. Velasco Santos: None; J. Esquivel-Valerio: None; M. Vázquez: None; M. Martinez de Filartiga: None; M. Alva Linares: None; R. Louis: None; C. Pizzarossa: None; A. Ralle: None; M. Riascos: None; J. Serventi: None; G. Alarcon: None; B. Pons-Estel: AstraZeneca, 1, 6, GSK, 1, 6, Janssen, 1, 6; G. Pons-Estel: Abbvie, 6, AstraZeneca, 1, 6, 12, Support to attend a scientific event, Boehringer-Ingelheim, 1, 2, 6, 12, Support to attend a scientific event, GSK, 1, 5, 6, Janssen, 1, 5, 6, Novartis, 1, 6, 12, Support to attend a scientific event, Pfizer, 1, 6, Remegen, 1, RemeGen, 1, 2, Remegen, 2, RemeGen, 5, 6, Remegen, 6, Sanofi, 1, 2, 5, 6, Werfen Diagnostics, 1, 2, 5, 6.

To cite this abstract in AMA style:

Nieto R, Hernandez L, Scolnik M, Subils G, Saurit V, Savio V, Arturi V, Kisluk B, González Lucero L, Grageda W, De Los Ángeles Gargiulo M, MONTICIELO O, Duarte A, Borba E, Parente L, Reis Neto E, Neira O, Aroca Martínez G, Iglesias Gamarra A, Méndez-Patarroyo P, López R, Hernandez M, Núñez-Álvarez C, González Bello Y, Velasco Santos J, Esquivel-Valerio J, Vázquez M, Martinez de Filartiga M, Alva Linares M, Louis R, Pizzarossa C, Ralle A, Riascos M, Serventi J, Alarcon G, Pons-Estel B, Pons-Estel G. Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/frequency-and-associated-factors-of-herpes-zoster-infection-in-systemic-lupus-erythematosus-patients-from-latin-america/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-and-associated-factors-of-herpes-zoster-infection-in-systemic-lupus-erythematosus-patients-from-latin-america/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology